Refine by
Cell Derived Autologous Therapies Equipment & Supplies In Nepal
16 equipment items found
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 1101 (CLTX CAR T) is an optimized first-in-class CAR T cell therapy that uniquely utilizes Chlorotoxin (CLTX), a 36-amino acid peptide derived from deathstalker scorpion venom as its tumour targeting ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 2101 (CDH17 CAR T) is an optimized 3rd generation CAR T cell therapy that is the first to target ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
T cells are part of our adaptive immune system – the system that tailors the body’s response to specific pathogens. Rather than generically attack any antigens, T cells circulate until they encounter a specific antigen, playing a critical part in immunity to foreign ...
Manufactured by:Xcell Biosciences Inc. based inSan Francisco, CALIFORNIA (USA)
Cell therapy manufacturing re-imagined. An automated, closed system for the production of autologous cell therapies. The KALI Cell Foundry is currently available for licensing ...
by:VetStem Biopharma based inPoway, CALIFORNIA (USA)
VetStem Regenerative Cells – Key Safety Factors: Autologous (from the patient back to the same patient): Tissue reaction risk is minimized. Minimally manipulated: Cells are not differentiated or modified. Accurate determination of each dose. Quality assessment of each dose. VetStem employs stringent processing protocols and quality control methods. Hundreds of publications support the ...
Manufactured by:Celularity Inc. based inFlorham Park, NEW JERSEY (USA)
Celularity’s unique technology realizes the full promise of cell therapies by harnessing the immunomodulatory and regenerative properties of the postpartum ...
by:TQ Therapeutics GmbH based inPlanegg, GERMANY
TQx is developing a modular target cell-specific modification platform including relevant technology components for the generation of gene modified cell therapy ...
Manufactured by:U.S. Stem Cell, Inc. (USRM) based inSunrise, FLORIDA (USA)
MyoCell SDF-1 has received approval from the FDA to begin human clinical trials and is intended to be an improvement to MyoCell. The myoblast cells to be injected are gene-modified prior to injection by an adenovirus vector so that they will release extra quantities of stromal derived factor – 1 or SDF-1 protein. Following injury which results in inadequate blood flow to the heart, such as ...
Manufactured by:RepliCel Life Sciences based inVancouver, BRITISH COLUMBIA (CANADA)
RCH-01 is a proprietary autologous cell therapy being developed to treat pattern baldness.* *This product is currently in clinical testing and not yet commercially available. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. Though several cell types are involved, dermal sheath cup cells, located at base of ...
Manufactured by:Lupagen Inc. based inDallas, TEXAS (USA)
Lupagen avoids the cost & complexity of cell therapy and the safety & clinical challenges of viral-based gene therapy by a simple patient-connected gene delivery procedure done at the bedside. Our Side CAR-T® delivery system, a first-in-class bedside system enables gene delivery directly to target cells in a highly-controlled and safe environment before reinfusing therapies to the ...
Manufactured by:RepliCel Life Sciences based inVancouver, BRITISH COLUMBIA (CANADA)
RCS-01 is a proprietary autologous cell therapy being developed to rejuvenate aging or UV-damaged skin.* *This product is currently in clinical testing and not yet commercially available. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells - a type of fibroblast cell - isolated from the hair follicle to repair and regenerate tissue. Though several cell types are ...
Manufactured by:IMPACT International GmbH based inKoln, GERMANY
ONE SYSTEM – MANY THERAPEUTIC OPTIONS. The innovative technology of IMPACT permits the preparation of variable concentrations of leukocytes and thrombocytes. And that, by means of a very simple automated preparation process. Scientifically tested IMPACT programs with specific parameters are recommended for each therapeutic goal. In addition, the system also permits the physician to define ...
Manufactured by:U.S. Stem Cell, Inc. (USRM) based inSunrise, FLORIDA (USA)
U.S. Stem Cell’s lead product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack. The procedure involves a physician removing a small amount of muscle from the patient’s thigh. From this muscle specimen, muscle stem cells (also called myoblasts) ...
Manufactured by:IMPACT International GmbH based inKoln, GERMANY
Autologous cell therapies make use of the natural endogenous mechanisms for the regeneration and healing of injured tissue. The body’s response to an injury is a complex healing cascade in order to heal the wound as quickly as possible. To understand how this regeneration process works, let us take a look into the cellular ...
Manufactured by:RepliCel Life Sciences based inVancouver, BRITISH COLUMBIA (CANADA)
RCT-01 is a proprietary autologous cell therapy being developed to treat chronically damaged tendons. * *This product is currently in clinical testing and not yet commercially available. RCT-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells - a type of fibroblast cell - isolated from the hair follicle to repair and regenerate tissue. Though several cell types are ...
Manufactured by:Minaris Regenerative Medicine, LLC based inAllendale, NEW JERSEY (USA)
At Minaris Regenerative Medicine, we are committed to bringing together and further developing highly talented, skilled, and dedicated experts with varied backgrounds applicable to gene and cell therapy manufacturing and development. Having this team creates the potential to accelerate your progress to market and to both anticipate and overcome your challenges, while reducing the overall cost and ...